Antihypertensives | Total | Without comorbidities | Comorbidities3 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Diabetes mellitus | Renal insufficiency | Hypercholesterolaemia | CHD | Post myocardial infarction | Heart failure | Stroke | Obesity | Asthma/COPD | |||
[N (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | [n (%)] | |
CCB1 | 527 (17.1) | 88 (18.6) | 55 (15.9) | 26 (20.5) | 97 (15.4) | 58 (14.5) | 12 (20.0) | 12 (18.8) | 56 (20.4) | 47 (13.6) | 76 (20.8) |
- with CAM2 | 14 | 5 | 2 | - | 1 | 1 | - | - | 2 | - | 3 |
Diuretic | 514 (16.7) | 77 (16.2) | 46 (13.3) | 27 (21.3) | 58 (9.2) | 73 (18.3) | 14 (23.3) | 15 (23.4) | 54 (19.6) | 63 (18.2) | 87 (23.8) |
- with CAM | 41 | 19 | 2 | 1 | 4 | 3 | - | - | 2 | 5 | 5 |
Beta-blocker | 882 (28.7) | 151 (31.9) | 113 (32.8) | 20 (15.7) | 225 (35.7) | 114 (28.5) | 11 (18.3) | 8 (12.5) | 61 (22.2) | 96 (27.7) | 83 (22.7) |
- with CAM | 36 | 13 | 3 | - | 8 | 3 | - | - | 4 | 2 | 3 |
ACE inhibitor | 729 (23.6) | 94 (19.8) | 75 (21.7) | 37 (29.1) | 147 (23.3) | 113 (28.3) | 17 (28.3) | 21 (32.8) | 79 (28.7) | 85 (24.6) | 61 (16.7) |
- with CAM | 33 | 6 | 4 | 3 | 6 | 9 | - | - | 2 | 2 | 1 |
Angiotensin II antagonist | 363 (11.8) | 64 (13.5) | 50 (14.5) | 11 (8.7) | 86 (13.6) | 38 (9.5) | 5 (8.3) | 7 (10.9) | 18 (6.5) | 48 (13.9) | 36 (9.8) |
- with CAM | 23 | 8 | 1 | 1 | 4 | 1 | - | - | 1 | 4 | 3 |
Alpha-1 blocker | 20 (0.7) | - | 1 (0.3) | 1 (0.8) | 4 (0.6) | 1 (0.3) | 1 (1.7) | - | 3 (1.1) | 3 (0.9) | 6 (1.6) |
- with CAM | - | - | - | - | - | - | - | - | - | - | - |
Antiadrenergic agent | 44 (1.4) | - | 5 (1.4) | 5 (3.9) | 14 (2.2) | 3 (0.8) | - | 1 (1.6) | 4 (1.5) | 4 (1.2) | 8 (2.2) |
- with CAM | 1 | - | - | - | - | - | - | - | - | - | 1 |
Total | 3088 (100) | 474 (100) | 345 (100) | 127 (100) | 631 (100) | 400 (100) | 60 (100) | 64 (100) | 275 (100) | 346 (100) | 366 (100) |